Rectal tuberculosis after infliximab therapy despite negative screening for latent tuberculosis in a patient with ulcerative colitis.
- Author:
Jatinderpal SINGH
1
;
Amarender S PURI
;
Sanjeev SACHDEVA
;
Puja SAKHUJA
;
Kulandaivelu ARIVARASAN
Author Information
- Publication Type:Case Report
- Keywords: Inflammatory bowel diseases; Colitis, ulcerative; Tumor necrosis factor-alpha; Tuberculosis; Adverse event
- MeSH: Adrenal Cortex Hormones; Colitis, Ulcerative*; Humans; Infliximab; Inflammatory Bowel Diseases; Latent Tuberculosis*; Mass Screening*; Necrosis; Tuberculosis*; Tumor Necrosis Factor-alpha; Ulcer*
- From:Intestinal Research 2016;14(2):183-186
- CountryRepublic of Korea
- Language:English
- Abstract: Tumor necrosis factor-α inhibitors are now considered as standard therapy for patients with severe inflammatory bowel disease who do not respond to corticosteroids, but they carry a definite risk of reactivation of tuberculosis. We present a case in which a patient with inflammatory bowel disease developed a de novo tuberculosis infection after the start of anti-tumor necrosis factor-α treatment despite showing negative results in tuberculosis screening. Although there are many case reports of pleural, lymph nodal and disseminated tuberculosis following infliximab therapy, we present the first case report of rectal tuberculosis following infliximab therapy.
